AB Pharmaceuticals

AB Pharmaceuticals is a US-based pharmaceutical company and a strategic subsidiary of Yuhan Corporation, South Korea's largest drugmaker. The company plays a dual role in Yuhan's global expansion strategy, managing the commercial distribution of generic medications while spearheading the clinical development of innovative therapeutic candidates in North America. Its most prominent program is Lazertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, which is being co-developed with Janssen Biotech. AB Pharmaceuticals also oversees a pipeline of novel treatments for metabolic diseases, including NASH and obesity, through partnerships with global leaders like Boehringer Ingelheim. By leveraging the extensive R&D resources of its parent company, AB Pharmaceuticals aims to bring high-value Korean innovations to the global healthcare market. The company is a key component of Yuhan's open innovation model, facilitating strategic collaborations and licensing deals with multinational pharmaceutical firms.